Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

Among patients hospitalized with community-acquired pneumonia in Georgia and Tennessee, 14% had pneumococcal pneumonia.

Pneumococcal conjugate vaccines (PCVs) have been highly effective in reducing pneumonia and other invasive infections caused by Streptococcus pneumoniae bacteria. But rates of meningitis have ...

The other new conjugate S. pneumoniae vaccine contains ten pneumococcal serotypes (PCV-7 serotypes plus serotypes 1, 5 and 7F) and contains protein D as a carrier for eight of the ten serotypes.

Protein conjugate bacterial vaccines for invasive pneumococcal diseases have revolutionized the epidemiology of invasive bacterial disease in young children in most of the developed world, but ...

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the ...